S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
CorMedix Inc. (CRMD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.4900 |
| Open | 3.5200 |
| Bid | 3.2700 x 1800 |
| Ask | 3.4100 x 1800 |
| Day's Range | 3.2800 - 3.5700 |
| 52 Week Range | 2.8700 - 8.3800 |
| Volume | |
| Avg. Volume | 370,937 |
| Market Cap | 127.97M |
| Beta (5Y Monthly) | 2.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7310 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.00 |
- GlobeNewswire
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern TimeBERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2022 and provided an update on recent business events. Recent Corporate Highlights: CorMedix announced on March 28 t
- GlobeNewswire
CorMedix Inc. Announces Leadership Updates and Operational Changes
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its international operations: Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10th. Liz Hurlburt, EVP of Clinical Operati
- GlobeNewswire
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2022, after the market close on Thursday, May 12, 2022, and will host a corporate update conference call at 4:30pm Eastern Time. Thursday, May 12th @ 4:
